Zomedica (ZOM)
(Delayed Data from AMEX)
$0.15 USD
0.00 (2.25%)
Updated May 3, 2024 04:00 PM ET
After-Market: $0.15 0.00 (3.31%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Zomedica Corp falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 25 | 19 | 4 | 0 | 0 |
Cost Of Goods | 8 | 5 | 1 | 0 | 0 |
Gross Profit | 17 | 14 | 3 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 49 | 36 | 24 | 17 | 20 |
Income After Depreciation & Amortization | -32 | -22 | -21 | -17 | -20 |
Non-Operating Income | -4 | 3 | 1 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -36 | -19 | -21 | -17 | -20 |
Income Taxes | -1 | -2 | -2 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -35 | -17 | -18 | -17 | -20 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -35 | -17 | -18 | -17 | -20 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -28 | -19 | -20 | -16 | -12 |
Depreciation & Amortization (Cash Flow) | 4 | 3 | 1 | 1 | 8 |
Income After Depreciation & Amortization | -32 | -22 | -21 | -17 | -20 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 979.95 | 979.92 | 956.53 | 364.45 | 106.30 |
Diluted EPS Before Non-Recurring Items | -0.02 | -0.02 | -0.05 | -0.03 | -0.19 |
Diluted Net EPS (GAAP) | -0.04 | -0.02 | -0.05 | -0.05 | -0.19 |
Fiscal Year end for Zomedica Corp falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 7.34 | 6.35 | 6.02 | 5.48 |
Cost Of Goods | NA | 2.26 | 1.99 | 1.97 | 1.65 |
Gross Profit | NA | 5.07 | 4.36 | 4.05 | 3.84 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 16.46 | 10.31 | 10.79 | 11.35 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -11.39 | -5.95 | -6.74 | -7.51 |
Non-Operating Income | NA | 1.13 | 3.60 | 1.48 | 1.39 |
Interest Expense | NA | 0.00 | 0.06 | 0.06 | 0.05 |
Pretax Income | NA | -21.95 | -2.41 | -5.33 | -6.18 |
Income Taxes | NA | 0.46 | -1.92 | -0.08 | 0.21 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -22.40 | -0.49 | -5.25 | -6.39 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -22.40 | -0.49 | -5.25 | -6.39 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 979.95 | 979.95 | 979.95 | 979.95 |
Diluted EPS Before Non-Recurring Items | NA | -0.01 | 0.00 | -0.01 | -0.01 |
Diluted Net EPS (GAAP) | NA | -0.02 | 0.00 | -0.01 | -0.01 |